Faecal lysozyme: determination, reference intervals and some data in gastro-intestinal disease

Costongs, G. M. P. J.; Hemrika, M.H.; Engels, L.G.J.B.; Bos, L.P.; Baş, Bülent; Flendrig, J. A.; Janson, Paul

doi:10.1016/0009-8981(87)90365-2

Cited by 15 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this paper we further demonstrate that the Adnab-9 antigen is constitutively expressed in the normal distal small bowel and colon in a young transplant donor, albeit at low levels. Paneth cells contain lysozyme, and some workers have observed increased levels of lysozyme in the feces of patients with CRC (40,41). 6, and may be analogous to the limited localization of CEA at gut surface/organ interfaces, as has been described in the fetal proximal gut (37).…”

Section: Discussionmentioning

confidence: 84%

Mucosal Origin and Shedding of an Early Colonic Tumor Marker Defined by Adnab-9 Monoclonal Antibody

Tobi

Elitsur

Moyer

et al. 1993

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Recent attention has been drawn to the diagnostic potential of tests based on shed colonic tumor markers. Adnab-9 monoclonal antibody raised against neoplastic, potentially premalignant colonic adenomas recognizes a marker in colonic effluent or tissue which correlates with the presence of tumors or risk of colorectal cancer. The origin of this antigen and optimal collection of colonic effluent were investigated by enzyme-linked immunosorbent assay and Western blotting. Mean Adnab-9 binding in effluent samples from colorectal cancer patients even after resection is high as compared with that in normal subjects (P < 0.05). Effluent samples are best collected in the morning hours. Antigen proteolysis may be significant depending on the site and timing of effluent collection, but breakdown products are reactive. Tissue and effluent Adnab-9 binding at any one anatomic site of collection appear to correlate (r = 0.88, P = 0.01). The Adnab-9 antigen is constitutively expressed at low levels throughout the distal bowel and localized to the deepest regions of the mucosal crypts. Other than meconium, no significant levels of binding are found in other body fluids. This antigen is specific for the gastrointestinal tract, its binding in conveniently collected effluent samples correlates with tissue content, and the antigen is constitutively expressed in the crypts of the distal small bowel and colonic mucosa.

show abstract

Section: Discussionmentioning

confidence: 84%

Mucosal Origin and Shedding of an Early Colonic Tumor Marker Defined by Adnab-9 Monoclonal Antibody

Tobi

Elitsur

Moyer

et al. 1993

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…26 Previous studies have provided support that fecal lysozyme can be used to assess disease activity in IBD 27 and to discriminate IBD and colorectal cancer from healthy controls and from functional bowel disorders. 28 To date, there is no direct comparison of Lf, Cal, PMN-e, and Lys in UC with reference to a clinical index for disease activity. We therefore aimed to evaluate the performance of the 4 widely used fecal parameters, Lf, Cal, PMN-e, and Lys, with reference to the CAI in patients with active and inactive UC in an outpatient setting.…”

Section: Discussionmentioning

confidence: 99%

“…In UC, fecal lysozyme originates to large parts from intestinal loss of granulocytes and their secretory granules 26. Previous studies have provided support that fecal lysozyme can be used to assess disease activity in IBD27 and to discriminate IBD and colorectal cancer from healthy controls and from functional bowel disorders 28…”

mentioning

confidence: 99%

Comparison of 4 Neutrophil-Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis

Langhorst

Elsenbruch

Mueller

et al. 2005

Inflammatory Bowel Diseases

129

View full text Add to dashboard Cite

show abstract

“…Using this model, peptidoglycan polysaccharide complexes from output of an ileostoma patient (but not from a healthy subject) induced severe chronic joint inflammation [18]. In the intestinal contents of patients with Crohn's disease, lysozyme levels are enhanced [19,20]. Results in the same study show that the peptidoglycan polysaccharide complexes of patients with Crohn's disease are more susceptible to lysozyme treatment.…”

Section: Discussionmentioning

confidence: 93%

Isolation and characterization of the viscous, high-molecular-mass microbial carbohydrate fraction from faeces of healthy subjects and patients with Crohn's disease and the consequences for a therapeutic approach

Embden

Lieshout

BINNEMA³

et al. 1998

Clinical Science

View full text Add to dashboard Cite

1. An earlier study by our group revealed that the viscosity of faeces from patients with Crohn's disease is significantly lower than that of healthy subjects. This is due to low concentrations of a high-molecular-mass carbohydrate, probably of bacterial origin. The cause of this phenomenon might be the impaired barrier function of the gut mucosa. Low viscosity may allow close contact of intestinal contents (bacterial products and toxins) with the intestinal wall. This could play a role in the maintenance of the disease.2. The first aim of this study was to investigate the high-molecular-mass carbohydrate fraction, responsible for viscosity, in detail. We also tried (in a pilot study) to raise the intestinal viscosity of patients with Crohn's disease with the undegradable food additive hydroxypropylcellulose (E463), in an attempt to alleviate clinical symptoms.3. The high-molecular-mass fraction (>300 kDa) responsible for faecal viscosity was sensitive to lysozyme and contained high levels of muramic acid. It was concluded that this material consisted mainly of peptidoglycan polysaccharides and was consequently of bacterial origin. The muramic acid in material from patients with Crohn's disease was 7.5 (1.5-13.9)%, which was less than in healthy subjects [11.4 (8.5-24.1)%; P=0.0004]. Furthermore, viscosity in material from patients with Crohn's disease was found to be half [14.9 (1.0-33.6) cP] of that found in healthy subjects [35.0 (2.7-90.7) cP; P=0.004].4.A daily dose of 1 g of hydroxypropylcellulose caused an increase in faecal viscosity in patients with Crohn's disease (from 1.4 to 2.3 cP) and in healthy subjects (from 4.9 to 7.5 cP). Faecal consistency improved in patients with Crohn's disease (from watery and loose to formed) and the defecation frequency decreased from 3-4 to about 2 times a day. No changes in defecation patterns were found in healthy subjects.5. These data indicate that the high-molecular-mass fraction that is responsible for faecal viscosity is peptidoglycan. Furthermore, a daily dose of a hydroxypropylcellulose solution to increase the viscosity of the intestinal contents of patients with Crohn's disease might be beneficial. This approach merits further study.

show abstract

Faecal lysozyme: determination, reference intervals and some data in gastro-intestinal disease

Cited by 15 publications

References 23 publications

Mucosal Origin and Shedding of an Early Colonic Tumor Marker Defined by Adnab-9 Monoclonal Antibody

Mucosal Origin and Shedding of an Early Colonic Tumor Marker Defined by Adnab-9 Monoclonal Antibody

Comparison of 4 Neutrophil-Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis

Isolation and characterization of the viscous, high-molecular-mass microbial carbohydrate fraction from faeces of healthy subjects and patients with Crohn's disease and the consequences for a therapeutic approach

Contact Info

Product

Resources

About